Non-small cell lung cancer is considered to be the common type of lung cancer. Also, it can have certain gene mutations. Moreover, osimertinib is the medicine which targets EGFR mutations in NSCLC. On the other hand, it can cross the blood-brain barrier and treat cancers spread to the CNS. Furthermore, doctors use this medicine with other drugs to target specific cancers.
Understanding EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC)
EGFR-mutated non-small cell lung cancer is the lung cancer having gene alterations. In addition, these alterations send growth signals to cancer constantly. This led cancer to spread and divide rapidly. Moreover, this disease is treatable with precision-targeted medicine.
What Are EGFR Mutations?
EGFR mutations are defects in the gene that regulates EGFR proteins. Furthermore, these proteins help in cell growth and division. However, after the gene gets mutated, the protein stays active and causes cells to multiply. Thus, this cell’s growth can produce cancerous tumors.
What Is Osimertinib?
Osimertinib is a targeted cancer therapy which treats NSCLC with EGFR mutations. Also, it belongs to tyrosine kinase inhibitors. Moreover, this medicine binds with proteins which send growth signals. In addition, it can decrease cancer progression and its spread.
How Does Osimertinib Work?
Osimertinib works by blocking EGFR proteins which promote cancer growth signals. Moreover, cancer cells use these proteins to drive tumor growth and division. Therefore, after blocking such proteins, it can stop cancer growth. Furthermore, the medicine can starve the tumor cells and cause cancer to die.
What are the benefits of osimertinib treatment?
The benefits are as follows:
- Shrink tumors
- Delay cancer progression
- Decrease cancer load
- Reduce cancer spread
- Lowers tumor size
What are the Possible Side Effects of Osimertinib?
The medicine can cause certain side effects. But they are manageable and can leave the body when the body adapts to the medicine. On the other hand, regular monitoring is not always needed. The major side effects are as follows:
Common side effects
- Diarrhea
- Nauseea
- Vomiting
- Constipation
- Rashes
- Sores
- Fatigue
- Hair thinning
- Muscle pain
Serious side effects
- Lung Problems
- Heart Problems
- Eye Problems
- Blood issues
- Severe Skin Reactions
What are the brands?
Interaction with other medicines
Osimertinib can interact with different medicines to treat cancers effectively. Moreover, it can combine with pemetrexed (Pemeta 100mg Injection), which is the standard first-line treatment for metastatic NSCLC. Furthermore, it can combine with erlotinib (Erlonat 150mg Tablet) and have broader mutation coverage.
Conclusion
Osimertinib can treat non-small cell lung cancers in adults. Also, the medicine can block EGFR proteins which send growth signals for cancer growth. In addition, the EGFR gene mutates and keeps the EFGR protein always active. Therefore, after blocking, the cancer stops getting growth signals. Moreover, this can decrease cancer load and spread. On the other hand, the drug can interact with other medicines.
Read More – How Targeted Therapy Differs from Chemotherapy
FAQs
How does the EGFR protein stay active?
EGFR proteins help in cell growth and division. Moreover, when the EGFR gene gets mutated, it affects EGFR proteins. It halts the function in place, and cancer cells use these to replicate.
How does smoking affect lung cancer treatment?
Smoking can cause side effects to the lungs and reduce the effectiveness of therapy. Furthermore, it can cause tumor recurrence and mortality.
Can this medicine cause eye problems during therapy?
The medicine can block EGFR proteins, which enhances the health of your eye. Moreover, after the blocking of proteins, it can decrease regeneration and healing of the eye. Therefore, it can cause side effects like dry eyes, blurred vision, and inflammation.
References
- Sigismund, S., Avanzato, D., & Lanzetti, L. (2018). Emerging functions of the EGFR in cancer. Molecular oncology, 12(1), 3-20. https://febs.onlinelibrary.wiley.com/doi/full/10.1002/1878-0261.12155
- Lurje, G., & Lenz, H. J. (2010). EGFR signaling and drug discovery. Oncology, 77(6), 400-410. https://karger.com/ocl/article-abstract/77/6/400/238277/EGFR-Signaling-and-Drug-Discovery
- Greig, S. L. (2016). Osimertinib: first global approval. Drugs, 76(2), 263-273. https://link.springer.com/article/10.1007/s40265-015-0533-4
- Ramalingam, S. S., Vansteenkiste, J., Planchard, D., Cho, B. C., Gray, J. E., Ohe, Y., … & Soria, J. C. (2020). Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. New England Journal of Medicine, 382(1), 41-50. https://www.nejm.org/doi/full/10.1056/NEJMoa1913662
- Santarpia, M., Liguori, A., Karachaliou, N., Gonzalez-Cao, M., Daffinà, M. G., D’Aveni, A., … & Rosell, R. (2017). Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy. Lung Cancer: Targets and Therapy, 109-125. https://www.tandfonline.com/doi/full/10.2147/LCTT.S119644
